Pharmacotherapy for the obese patient.
The long-term safety of many antiobesity pharmacologic regimens has not been adequately evaluated. If recommended and prescribed, pharmacologic agents should be an adjunct to a structured diet and exercise regimen. Unfortunately, weight gain after discontinuation of antiobesity agents is common. In addition, the effect of weight loss obtained through the use of pharmacotherapeutic agents on overall morbidity and mortality has not been established.
Dickerson
Lori M
LM
Department of Family Medicine, Medical University of South Carolina, 9228 Medical Plaza Drive, Charleston, SC 29406, USA. macfarll@musc.edu
Carek
Peter J
PJ
D018663:Adrenergic Agents / Q000627:therapeutic use; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use*; D015992:Body Mass Index; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D018490:Serotonin Agents / Q000627:therapeutic use
D018663:Adrenergic Agents; D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D018490:Serotonin Agents